OTC · LFLY
Leafly Holdings, Inc.
$37.00$0.00 (0.0%)
Leafly Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.78% below the high.
Loading market information…
NASDAQ · VIRI · USD
Stock price, earnings
Quote as of Oct 8, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Virios Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.4% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Virios Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Virios Therapeutics, Inc. is a biotechnology firm in its development phase, dedicated to pioneering antiviral treatments for conditions that arise from an unusual immune response triggered by viral infections. Its primary investigational compound, IMC-1, is a precisely formulated blend of famciclovir and celecoxib, currently being developed to address fibromyalgia. Additionally, the company is advancing IMC-2, a therapeutic combination of valacyclovir and celecoxib, aimed at mitigating the various long COVID symptoms, including ongoing fatigue, sleep disturbances, cognitive challenges, pain, autonomic dysfunction, and anxiety. Founded in 2012, the organization was initially known as Virios Therapeutics, LLC, before officially changing its name to Virios Therapeutics, Inc. in December 2020. The company's headquarters are located in Alpharetta, Georgia.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:42 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2022 |
|---|
| Nov 14, 2022 |
| -$0.28+42.86% vs estimate |
| $0.00 |
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$37.00$0.00 (0.0%)
Leafly Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.78% below the high.
$0.90$0.00 (0.0%)
Atlantic International Corp.’s quoted price sits in the lower half of its reported 52-week range, 82.86% below the high.
$0.63$0.00 (0.0%)
LakeShore Biopharma Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 92.71% below the high.
$0.07-$0.10 (-60.05%)
TFF Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.41% below the high.
$0.50$0.00 (0.0%)
TC Biopharm (Holdings) Plc’s quoted price sits in the lower half of its reported 52-week range, 99.9% below the high.
$0.37$0.00 (0.0%)
Seelos Therapeutics, Inc.: Healthcare · Biotechnology.
$0.31+$0.08 (+36.94%)
Akerna Corp.’s quoted price sits in the lower half of its reported 52-week range, 98.46% below the high.
$0.01-$0.01 (-36.84%)
Bellerophon Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.0% below the high.
